z-logo
open-access-imgOpen Access
Lomustine, cytarabine, cyclophosphamide, etoposide – An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors
Author(s) -
Alok Gupta,
Anant Gokarn,
Deepan Rajamanickam,
Sachin Punatar,
Ravi Thippeswamy,
Libin Mathew,
Bhausaheb Bagal,
Sadhana Kannan,
Navin Khattry
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.181183
Subject(s) - medicine , etoposide , gastroenterology , lomustine , mucositis , surgery , cyclophosphamide , cytarabine , transplantation , hematopoietic stem cell transplantation , chemotherapy , oncology , vincristine
High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) is the treatment of choice for patients with relapsed and refractory (RR) lymphoma. We analyzed toxicity and long-term outcome with lomustine, cytarabine, cyclophosphamide, etoposide (LACE) conditioning in patients with primary refractory or relapsed lymphoma undergoing autologous transplant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here